



December 21, 2022

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative
Director and President
(TSE Growth Code: 4592)
Contact: Yoshihiro Kakutani, Corporate
Officer of Management
Administration
(TEL. +81-3-6264-3481)

Establishment of In-house Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products

SanBio Co., Ltd. (headquarters: Chuo-ku, Tokyo, Representative Director and President: Keita Mori) hereby announces that it has established an in-house facility for packaging, labeling and storage of regenerative medicine products and obtained a license for packaging, labeling and storage of regenerative medicine products on December 15, 2022.

This development has minimal impact on the consolidated earnings forecast for the fiscal year ending January 31, 2023, and its impact has already been factored into the forecast.



December 21, 2022

SanBio Co., Ltd.

**Establishment of In-House Facility and Acquisition of License for Packaging,
Labeling and Storage of Regenerative Medicine Products**

SanBio Co, Ltd. (headquarters: Chuo-ku, Tokyo, Representative Director and President: Keita Mori) hereby announces that it has established an in-house facility for packaging, labeling and storage of regenerative medicine products (hereafter, the “Facility”) and that on December 15, 2022, it obtained a license for packaging, labeling and storage of regenerative medicine products.

The Company’s pipeline product SB623 is currently under review by regulatory authorities for approval as a treatment for chronic effects of traumatic brain injury. The Company is in the process of building a distribution network to ensure smooth and seamless delivery of the product to patients after its approval. This includes developing R-SAT[®], a distribution management and administration schedule support system for regenerative medicine products. The Company decided to establish the Facility to flexibly respond to the needs of medical institutions. Following a review of its quality management systems by the regulatory authorities, the Company was granted a license to package, label and store regenerative medicine products at the Facility. This is a significant step in the Company’s ongoing efforts to establish a seamless and efficient distribution network.

Facility overview

Location: Chuo-ku, Tokyo

Size: 54.47m²

Purpose: Packaging, Labeling and Storage of Regenerative Medicine Products

For more information, contact:

SanBio Co., Ltd.

Management Administration

Email: info@sanbio.jp